The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization
Open accessAbstract
Background: Programmed death 1 (PD‐1) is an immunologic checkpoint that limits immune responses by delivering potent inhibitory signals to T cells on interaction with specific ligands expressed on tumor/virus‐infected cells, thus contributing to immune escape mechanisms. Therapeutic PD‐1 blockade has been shown to mediate tumor eradication with impressive clinical results. Little is known about the expression/function of PD‐1 on human natural killer (NK) cells. Objective: We sought to clarify whether human NK cells can express PD‐1 and analyze their phenotypic/functional features. Methods: We performed multiparametric cytofluorimetric analysis of PD‐1+ NK cells and their functional characterization using degranulation, cytokine production, and proliferation assays. Results: We provide unequivocal evidence that PD‐1 is highly expressed (PD‐1bright) on an NK cell subset detectable in the peripheral blood of approximately one fourth of healthy subjects. These donors are always serologically positive for human cytomegalovirus. PD‐1 is expressed by CD56dim but not CD56bright NK cells and is confined to fully mature NK cells characterized by the NKG2A−KIR+CD57+ phenotype. Proportions of PD‐1bright NK cells were higher in the ascites of a cohort of patients with ovarian carcinoma, suggesting their possible induction/expansion in tumor environments. Functional analysis revealed a reduced proliferative capability in response to cytokines, low degranulation, and impaired cytokine production on interaction with tumor targets. Conclusions: We have identified and characterized a novel subpopulation of human NK cells expressing high levels of PD‐1. These cells have the phenotypic characteristics of fully mature NK cells and are increased in patients with ovarian carcinoma. They display low proliferative responses and impaired antitumor activity that can be partially restored by antibody‐mediated disruption of PD‐1/programmed death ligand interaction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986
Activation of NK Cells and T Cells by NKG2D, a Receptor for Stress-Inducible MICA
Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J. H., Lanier, L. L., & Spies, T. (1999) · Science · doi:10.1126/science.285.5428.727 · Cited by 2,999
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
Day, C. L., Kaufmann, D. E., Kiepiela, P., Brown, J. A., Moodley, E. S., Reddy, S., Mackey, E. W., Miller, J. D., Leslie, A. J., DePierres, C., et al. (2006) · Nature · doi:10.1038/nature05115 · Cited by 2,680
HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C
Braud, V. M., Allan, D. S. J., O'Callaghan, C. A., Söderström, K., D'Andrea, A., Ogg, G. S., Lazetic, S., Young, N. T., Bell, J. I., Phillips, J. H., et al. (1998) · Nature · doi:10.1038/35869 · Cited by 2,227
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072
Caligiuri, M. A. (2008) · Blood · doi:10.1182/blood-2007-09-077438 · Cited by 1,905
Activating Receptors and Coreceptors Involved in Human Natural Killer Cell-Mediated Cytolysis
Moretta, A., Bottino, C., Vitale, M., Pende, D., Cantoni, C., Mingari, M. C., Biassoni, R., & Moretta, L. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.197 · Cited by 1,778
Self-citationLanier, L. L. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.359 · Cited by 1,648
Inhibitory B7-family molecules in the tumour microenvironment
Zou, W., & Chen, L. (2008) · Nature Reviews Immunology · doi:10.1038/nri2326 · Cited by 1,608
Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes
Agata, Y., Kawasaki, A., Nishimura, H., Ishida, Y., Tsubat, T., Yagita, H., & Honjo, T. (1996) · International Immunology · doi:10.1093/intimm/8.5.765 · Cited by 1,589
MHC class I molecules and kirs in human history, health and survival
Parham, P. (2005) · Nature Reviews Immunology · doi:10.1038/nri1570 · Cited by 1,203
Hamanishi, J., Mandai, M., Ikeda, T., Minami, M., Kawaguchi, A., Murayama, T., Kanai, M., Mori, Y., Matsumoto, S., Chikuma, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.3397 · Cited by 1,180
Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity
Hirano, F., Kaneko, K., Tamura, H., Dong, H., Wang, S., Ichikawa, M., Rietz, C., Flies, D. B., Lau, J. S., Zhu, G., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.1089.65.3 · Cited by 1,018
Okazaki, T., Chikuma, S., Iwai, Y., Fagarasan, S., & Honjo, T. (2013) · Nature Immunology · doi:10.1038/ni.2762 · Cited by 916
RECEPTORS FOR HLA CLASS-I MOLECULES IN HUMAN NATURAL KILLER CELLS
Moretta, A., Bottino, C., Vitale, M., Pende, D., Biassoni, R., Mingari, M. C., & Moretta, L. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.619 · Cited by 875
Self-citationImprint of human cytomegalovirus infection on the NK cell receptor repertoire
Gumá, M., Angulo, A., Vilches, C., Gómez-Lozano, N., Malats, N., & López-Botet, M. (2004) · Blood · doi:10.1182/blood-2004-05-2058 · Cited by 865
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
Ohaegbulam, K. C., Assal, A., Lazar-Molnar, E., Yao, Y., & Zang, X. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.10.009 · Cited by 843
Benson, D. M., Bakan, C. E., Mishra, A., Hofmeister, C. C., Efebera, Y., Becknell, B., Baiocchi, R. A., Zhang, J., Yu, J., Smith, M. K., et al. (2010) · Blood · doi:10.1182/blood-2010-02-271874 · Cited by 807
Schlums, H., Cichocki, F., Tesi, B., Theorell, J., Beziat, V., Holmes, T. D., Han, H., Chiang, S. C. C., Foley, B., Mattsson, K., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.02.008 · Cited by 787
Blank, C., Brown, I., Peterson, A. C., Spiotto, M., Iwai, Y., Honjo, T., & Gajewski, T. F. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3259 · Cited by 772
Lopez-Vergès, S., Milush, J. M., Pandey, S., York, V. A., Arakawa-Hoyt, J., Pircher, H., Norris, P. J., Nixon, D. F., & Lanier, L. L. (2010) · Blood · doi:10.1182/blood-2010-04-282301 · Cited by 752
Björkström, N. K., Riese, P., Heuts, F., Andersson, S., Fauriat, C., Ivarsson, M. A., Björklund, A. T., Flodström-Tullberg, M., Michaëlsson, J., Rottenberg, M. E., et al. (2010) · Blood · doi:10.1182/blood-2010-04-281675 · Cited by 734
Brandt, C. S., Baratin, M., Yi, E. C., Kennedy, J., Gao, Z., Fox, B., Haldeman, B., Ostrander, C. D., Kaifu, T., Chabannon, C., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090681 · Cited by 706
Self-citationTumor Immunotherapy Directed at PD-1
Ribas, A. (2012) · New England Journal of Medicine · doi:10.1056/nejme1205943 · Cited by 683
Mavilio, D., Lombardo, G., Benjamin, J., Kim, D., Follman, D., Marcenaro, E., O'Shea, M. A., Kinter, A., Kovacs, C., Moretta, A., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409872102 · Cited by 544
Self-citationB7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma.
Strome, S. E., Dong, H., Tamura, H., Voss, S. G., Flies, D. B., Tamada, K., Salomão, D. R., Cheville, J. C., Hirano, F., Lin, W. Y., et al. (2003) · PubMed · Cited by 489
Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells
Odorizzi, P. M., Pauken, K. E., Paley, M. A., Sharpe, A., & Wherry, E. J. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20142237 · Cited by 467
Expansion of CD94/NKG2C+ NK cells in response to human cytomegalovirus-infected fibroblasts
Gumá, M., Budt, M., Sáez, A., Brckalo, T., Hengel, H., Angulo, A., & López-Botet, M. (2006) · Blood · doi:10.1182/blood-2005-09-3682 · Cited by 449
Moretta, A., Sivori, S., Vitale, M., Pende, D., Morelli, L., Augugliaro, R., Bottino, C., & Moretta, L. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.3.875 · Cited by 447
Self-citationPD‐1 as a potential target in cancer therapy
McDermott, D. F., & Atkins, M. B. (2013) · Cancer Medicine · doi:10.1002/cam4.106 · Cited by 414
PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model
Zhang, L., Gajewski, T. F., & Kline, J. (2009) · Blood · doi:10.1182/blood-2009-03-206672 · Cited by 411
Bour‐Jordan, H., Esensten, J. H., Martinez‐Llordella, M., Penaranda, C., Stumpf, M., & Bluestone, J. A. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01011.x · Cited by 391
Immunoreceptor tyrosine-based inhibition motifs
Vivier, E., & Daëron, M. (1997) · Immunology Today · doi:10.1016/s0167-5699(97)80025-4 · Cited by 351
Ishida, M., Iwai, Y., Tanaka, Y., Okazaki, T., Freeman, G. J., Minato, N., & Honjo, T. (2002) · Immunology Letters · doi:10.1016/s0165-2478(02)00142-6 · Cited by 280
Human Cytomegalovirus Drives Epigenetic Imprinting of the IFNG Locus in NKG2Chi Natural Killer Cells
Luetke-Eversloh, M., Hammer, Q., Durek, P., Nordström, K., Gasparoni, G., Pink, M., Hamann, A., Walter, J., Chang, H.-D., Dong, J., et al. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004441 · Cited by 256
Della Chiesa, M., Falco, M., Podestà, M., Locatelli, F., Moretta, L., Frassoni, F., & Moretta, A. (2012) · Blood · doi:10.1182/blood-2011-08-372003 · Cited by 254
Self-citationMoretta, L., Locatelli, F., Pende, D., Marcenaro, E., Mingari, M. C., & Moretta, A. (2011) · Blood · doi:10.1182/blood-2010-08-264085 · Cited by 229
Self-citationHuman natural killer cell deficiencies
Orange, J. S. (2006) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0b013e3280106b65 · Cited by 229
PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1
Ghiotto, M., Gauthier, L., Serriari, N., Pastor, S., Truneh, A., Nunes, J. A., & Olive, D. (2010) · International Immunology · doi:10.1093/intimm/dxq049 · Cited by 229
Self-citationNew regulatory co-receptors: inducible co-stimulator and PD-1
Okazaki, T., Iwai, Y., & Honjo, T. (2002) · Current Opinion in Immunology · doi:10.1016/s0952-7915(02)00398-9 · Cited by 226
Falco, M., Biassoni, R., Bottino, C., Vitale, M., Sivori, S., Augugliaro, R., Moretta, L., & Moretta, A. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.6.793 · Cited by 222
Self-citationBiochemical Signaling of PD-1 on T Cells and Its Functional Implications
Boussiotis, V. A., Chatterjee, P., & Li, L. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000059 · Cited by 185
Dissecting CD56dim human NK cells
Moretta, L. (2010) · Blood · doi:10.1182/blood-2010-09-303057 · Cited by 181
Self-citationB7-H6-mediated downregulation of NKp30 in NK cells contributes to ovarian carcinoma immune escape
Pesce, S., Tabellini, G., Cantoni, C., Patrizi, O., Coltrini, D., Rampinelli, F., Matta, J., Vivier, E., Moretta, A., Parolini, S., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2014.1001224 · Cited by 178
Self-citationMacFarlane, A. W., Jillab, M., Plimack, E. R., Hudes, G. R., Uzzo, R. G., Litwin, S., Dulaimi, E., Al-Saleem, T., & Campbell, K. S. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0133 · Cited by 177
Marcenaro, E., Chiesa, M. D., Bellora, F., Parolini, S., Millo, R., Moretta, L., & Moretta, A. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.7.3992 · Cited by 152
Self-citationBrunetta, E., Fogli, M., Varchetta, S., Bozzo, L., Hudspeth, K. L., Marcenaro, E., Moretta, A., & Mavilio, D. (2009) · Blood · doi:10.1182/blood-2009-06-226332 · Cited by 152
Self-citationAlvarez, I. B., Pasquinelli, V., Jurado, J. O., Abbate, E. H., Musella, R. M., de la Barrera, S., & García, V. (2010) · The Journal of Infectious Diseases · doi:10.1086/654932 · Cited by 126
Wiesmayr, S., Webber, S. A., Macedo, C., Popescu, I., Smith, L., Luce, J., & Metes, D. (2011) · European Journal of Immunology · doi:10.1002/eji.201141832 · Cited by 118
PD-1 Expression on Natural Killer Cells and CD8 + T Cells During Chronic HIV-1 Infection
Norris, S., Coleman, A., Kuri-Cervantes, L., Bower, M., Nelson, M. R., & Goodier, M. R. (2012) · Viral Immunology · doi:10.1089/vim.2011.0096 · Cited by 117
Min‐Oo, G., & Lanier, L. L. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20141172 · Cited by 115
PD-1/PD-L1 pathway and T-cell exhaustion in chronic hepatitis virus infection
Watanabe, T., Bertoletti, A., & Tan, A. T. (2010) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2010.01313.x · Cited by 95
Muntasell, A., López‐Montañés, M., Vera, A., Heredia, G., Romo, N., Peñafiel, J., Moraru, M., Vila, J., Vilches, C., & López‐Botet, M. (2013) · European Journal of Immunology · doi:10.1002/eji.201343773 · Cited by 92
Contributions of PD-1/PD-L1 pathway to interactions of myeloid DCs with T cells in atherosclerosis
Lee, J. H., Zhuang, Y., Wei, X., Shang, F., Wang, J., Zhang, Y., Liu, X., Yang, Y., Liu, L., & Zheng, Q. (2008) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2008.10.028 · Cited by 83
Marcenaro, E., Pesce, S., Sivori, S., Carlomagno, S., Moretta, L., & Moretta, A. (2013) · Blood · doi:10.1182/blood-2012-09-458752 · Cited by 45
Self-citationCiccone, E., Pende, D., Nannl, L., et al. (1995) · International Immunology · doi:10.1093/intimm/7.3.393 · Cited by 34
Wen-jin, Z., Chuanhui, P., Yunle, W., Lateef, S. A., & Shusen, Z. (2012) · BMC Gastroenterology · doi:10.1186/1471-230x-12-109 · Cited by 32
NK Cells and their Receptors during Viral Infections
Marcenaro, E., Carlomagno, S., Pesce, S., Chiesa, M. D., Parolini, S., Moretta, A., & Sivori, S. (2011) · Immunotherapy · doi:10.2217/imt.11.99 · Cited by 29
Self-citationPD-1 blockade: A promising immunotherapy for HIV?
Macatangay, B. J. C., & Rinaldo, C. R. (2009) · PubMed · Cited by 22
Uptake of CCR7 by KIR2DS4 + NK Cells Is Induced upon Recognition of Certain HLA-C Alleles
Pesce, S., Carlomagno, S., Moretta, A., Sivori, S., & Marcenaro, E. (2015) · Journal of Immunology Research · doi:10.1155/2015/754373 · Cited by 21
Self-citation
Cited by
Exploring the NK cell platform for cancer immunotherapy
Myers, J. A., & Miller, J. S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0426-7 · Cited by 1,276
Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)
Cossarizza, A., Chang, H., Radbruch, A., Acs, A., Adam, D., Adam‐Klages, S., Agace, W. W., Aghaeepour, N., Akdis, M., Allez, M., et al. (2019) · European Journal of Immunology · doi:10.1002/eji.201970107 · Cited by 979
Self-citationContribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
Hsu, J., Hodgins, J. J., Marathe, M., Nicolai, C. J., Bourgeois-Daigneault, M.-C., Trevino, T. N., Azimi, C. S., Scheer, A. K., Randolph, H. E., Thompson, T. W., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci99317 · Cited by 817
The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
Petitprez, F., Meylan, M., de Reyniès, A., Sautès-Fridman, C., & Fridman, W. H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00784 · Cited by 602
Human NK cells: surface receptors, inhibitory checkpoints, and translational applications
Sivori, S., Vacca, P., Del Zotto, G., Munari, E., Mingari, M. C., & Moretta, L. (2019) · Cellular & Molecular Immunology · doi:10.1038/s41423-019-0206-4 · Cited by 555
Self-citation
Metadata
- Authors
- Pesce, S., Greppi, M., Tabellini, G., Rampinelli, F., Parolini, S., Olive, D., Moretta, L., Moretta, A., & Marcenaro, E.
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2017-01
- Volume
- 139
- Issue
- 1
- Pages
- 335-346.e3
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W2397739282
- Cited by
- 465
- References
- 62
- FWCI
- 24.06
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.